Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Sparsentan, developed by Travere Therapeutics, is a dual receptor antagonist that significantly reduces proteinuria by simultaneously blocking endothelin type A (ETA) and angiotens···【more】
Article source：Captain MedicineRelease date：2026-03-18Recommended：40
Sparsentan, developed by Travere Therapeutics, is an endothelin and angiotensin II receptor antagonist. The drug received accelerated approval from the FDA in February 2023 for red···【more】
Article source：Captain MedicineRelease date：2026-03-18Recommended：44
During treatment with Sparsentan, regular monitoring is required. Follow-up should be conducted before treatment and monthly for the first 12 months, followed by evaluations every ···【more】
Article source：Captain MedicineRelease date：2026-03-18Recommended：45
Sparsentan is the first dual pathway blocker. Its usage and dosage should be determined based on each patient's specific condition. The recommended starting dose is 200 mg dail···【more】
Article source：Captain MedicineRelease date：2026-03-18Recommended：44
Elacestrant, an estrogen receptor antagonist developed by the Italian company Menarini, was first approved for marketing by the U.S. FDA on January 27, 2023. Subsequently, it has b···【more】
Article source：Captain MedicineRelease date：2026-03-16Recommended：45
Elacestrant, while exerting its therapeutic effects, can also cause some side effects. Patients taking Elacestrant need to closely monitor their own condition.Side Effects of Elace···【more】
Article source：Captain MedicineRelease date：2026-03-16Recommended：36
Regarding the dosage of elacestrant, in addition to the recommended dose, appropriate dose adjustments should be made based on the patient's individual condition.Recommended Ad···【more】
Article source：Captain MedicineRelease date：2026-03-16Recommended：44
Elacestrant is an estrogen receptor antagonist developed by the Italian company Menarini. It received its first approval from the U.S. Food and Drug Administration (FDA) on January···【more】
Article source：Captain MedicineRelease date：2026-03-16Recommended：48
Capmatinib is a targeted therapy for non-small cell lung cancer with MET exon 14 skipping mutations. For patients using this drug, the most crucial concerns are undoubtedly the pur···【more】
Article source：Captain MedicineRelease date：2026-03-13Recommended：40
Capmatinib (Tabrecta) is a highly selective MET receptor tyrosine kinase inhibitor that specifically inhibits MET receptors and the phosphorylation process of MET-mediated downstre···【more】
Article source：Captain MedicineRelease date：2026-03-13Recommended：57
Ixazomib, as a novel targeted therapy, blocks the growth and proliferation of tumor cells by inhibiting proteasome activity, providing an important treatment option for patients wi···【more】
Article source：Captain MedicineRelease date：2026-03-13Recommended：46
Ixazomib is an oral proteasome inhibitor primarily used clinically to treat multiple myeloma. As a novel targeted therapy, it inhibits proteasome activity, blocking tumor cell grow···【more】
Article source：Captain MedicineRelease date：2026-03-13Recommended：49
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2262025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4532024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2312025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2452025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2252025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2532025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2342025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2162025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
